Anti-CD20 (rituximab)

DRUG3 trials

Sponsors

Jean M. Tersak, M.D., National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), PolTREG S.A.

Conditions

Diabetes Mellitus, Type 1Diabetes Mellitus, Type INeuroblastomaOpsoclonus-myoclonusPresymptomatic Diabetes Type 1 (Stage 1)Type 1 Diabetes Mellitus

Phase 2

Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma

TerminatedNCT00202930

Jean M. Tersak, M.D.Neuroblastoma, Opsoclonus-myoclonus

Start: 2005-07-31End: 2009-02-05Updated: 2021-01-22

Rituximab in New Onset Type 1 Diabetes

CompletedNCT00279305

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Type 1 Diabetes Mellitus

Start: 2005-08-31End: 2009-11-30Updated: 2020-05-06

Treatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 Antibody

RecruitingNCT06688331

PolTREG S.A.Diabetes Mellitus, Type 1, Diabetes Mellitus, Type I, Presymptomatic Diabetes Type 1 (Stage 1)

Start: 2025-03-12End: 2032-12-01Target: 150Updated: 2026-07-17

Related Papers

How many unpublished studies? ClinicalTrials.gov (n = 2614 studies): diabetes | Closed Studies | Interventional Studies | Phase 3, 4 | Search Date: Oct 27, 2014

Figshare2014-01-01

Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.

2009-11-01802 citations